San Francisco, California, Dec 06, 2017: TMR Research has published a new report which is titled, “Cancer Gene Therapy Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.” The market for gene therapy is swiftly expanding is it may hold the potential to treat several genetic issues and other diseases. Cancer gene therapy is one of the branches and widely researched aspect of gene therapy. Thanks to the increasing interest from private organizations as well as funding received from government and other organizations, there has been much development in cancer gene therapy and it is becoming a feasible alternative for cancer treatment. As cancer gene therapy can save billions of lives, this market is expected to witness promising growth in the coming years. Cancer gene therapy comprises insertion of a functional gene into the cells of a cancer patient. This functional gene or therapeutic DNA can rectify the metabolism of the patient and repair the acquired genetic abnormality. The gene provides a new function to the cell.
As of now, the cancer gene therapy is being tested. Once this trial is over and the results are out the market is predicted to grow. A case in point would be a pharmaceutical company in the US going by the name Kite Pharma. This pharmaceutical company revealed its results from the first 6 months of the gene therapy trial called CAR-T cell therapy. The results revealed that cancer from one-third of the terminal patients had been eliminated. Such therapies are expected to propel the growth of the global cancer gene therapy market.
Of the various types of gene therapy approaches, immunotherapy, oncolytic virotherapy, and gene transfer are predicted to be promising. Vaccines that are being developed for cancer using gene therapy are also showing optimistic development. Lung cancer, malignant melanoma, prostate cancer, and pancreatic cancer will be treated by the use of these vaccines which make use of gene therapy that modifies the genetic information in materials so as to efficiently devise a treatment.
The global cancer gene therapy market is growing on account of technological breakthroughs. The rising trend and popularity of the emerging genomics technologies such as high-density DNA microarrays and next-generation sequencing and the government support such technologies receive for cancer treatment is additionally aiding the development of gene therapy market. There are various support programs such as screening programs for breast cancer control which is also supporting the demand for cancer gene therapy. Increasing incidences of various types of cancers all across the globe will remain the key driver for this market.
On the basis of geography, the global cancer gene therapy market can be segmented into Asia Pacific, North America, the Middle East and Africa, Latin America, and Europe. Europe and North America are showing much growth in the cancer gene therapy market thanks to the technological progress in these regions. The high population of aged people is also a factor driving the growth of this market in Europe and North America. Asia Pacific is also making a headway in the cancer gene therapy market as it receives impetus from improving economy, government initiatives, improving healthcare infrastructure, and rise in research and development.
The report profiles some of the prominent players operating in the global cancer gene therapy market such as: BioCancell, SiBiono, ZioPharm Oncology, Altor Bioscience Corporation, Shanghai Sunway Biotech Company Limited, GlobeImmune, Inc., OncoGeneX, Aduro Biotech, New Link Genetics., and GENELUX.
Get Sample Copy of this Report